Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowley, Fionnuala, Fitzgerald, Bailey G., Bhardwaj, Aarti S., Siraj, Irine, Smith, Cardinale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718495/
https://www.ncbi.nlm.nih.gov/pubmed/35005653
http://dx.doi.org/10.1016/j.jtocrr.2021.100260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718495/
https://www.ncbi.nlm.nih.gov/pubmed/35005653
http://dx.doi.org/10.1016/j.jtocrr.2021.100260

Ejemplares similares